vs
Bio-Techne（TECH）与福泰制药（VRTX）财务数据对比。点击上方公司名可切换其他公司
福泰制药的季度营收约是Bio-Techne的10.8倍（$3.2B vs $295.9M），福泰制药净利率更高（37.3% vs 12.8%，领先24.5%），福泰制药同比增速更快（9.5% vs -6.4%），过去两年福泰制药的营收复合增速更高（8.9% vs 4.2%）
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
福泰制药是总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略、而非组合化学方法开发药物的生物技术公司之一。除波士顿总部外，公司还在加州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心。
TECH vs VRTX — 直观对比
营收规模更大
VRTX
是对方的10.8倍
$295.9M
营收增速更快
VRTX
高出16.0%
-6.4%
净利率更高
VRTX
高出24.5%
12.8%
两年增速更快
VRTX
近两年复合增速
4.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $295.9M | $3.2B |
| 净利润 | $38.0M | $1.2B |
| 毛利率 | 64.6% | 85.4% |
| 营业利润率 | 18.4% | 37.8% |
| 净利率 | 12.8% | 37.3% |
| 营收同比 | -6.4% | 9.5% |
| 净利润同比 | 68.3% | 30.5% |
| 每股收益（稀释后） | $0.24 | $4.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TECHVRTX
| Q4 25 | $295.9M | $3.2B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | $317.0M | $3.0B | ||
| Q1 25 | $316.2M | $2.8B | ||
| Q4 24 | $297.0M | $2.9B | ||
| Q3 24 | $289.5M | $2.8B | ||
| Q2 24 | $306.1M | $2.6B | ||
| Q1 24 | $303.4M | $2.7B |
净利润TECHVRTX
| Q4 25 | $38.0M | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $-17.7M | $1.0B | ||
| Q1 25 | $22.6M | $646.3M | ||
| Q4 24 | $34.9M | $913.0M | ||
| Q3 24 | $33.6M | $1.0B | ||
| Q2 24 | $40.6M | $-3.6B | ||
| Q1 24 | $49.1M | $1.1B |
毛利率TECHVRTX
| Q4 25 | 64.6% | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | 62.7% | 86.3% | ||
| Q1 25 | 67.9% | 86.9% | ||
| Q4 24 | 65.3% | 85.5% | ||
| Q3 24 | 63.2% | 85.8% | ||
| Q2 24 | 66.4% | 85.9% | ||
| Q1 24 | 67.4% | 87.3% |
营业利润率TECHVRTX
| Q4 25 | 18.4% | 37.8% | ||
| Q3 25 | — | 38.6% | ||
| Q2 25 | -7.5% | 38.8% | ||
| Q1 25 | 12.2% | 22.7% | ||
| Q4 24 | 16.0% | 35.2% | ||
| Q3 24 | 13.8% | 40.3% | ||
| Q2 24 | 15.0% | -132.9% | ||
| Q1 24 | 22.1% | 42.4% |
净利率TECHVRTX
| Q4 25 | 12.8% | 37.3% | ||
| Q3 25 | — | 35.2% | ||
| Q2 25 | -5.6% | 34.8% | ||
| Q1 25 | 7.1% | 23.3% | ||
| Q4 24 | 11.7% | 31.4% | ||
| Q3 24 | 11.6% | 37.7% | ||
| Q2 24 | 13.3% | -135.8% | ||
| Q1 24 | 16.2% | 40.9% |
每股收益（稀释后）TECHVRTX
| Q4 25 | $0.24 | $4.64 | ||
| Q3 25 | — | $4.20 | ||
| Q2 25 | $-0.11 | $3.99 | ||
| Q1 25 | $0.14 | $2.49 | ||
| Q4 24 | $0.22 | $3.62 | ||
| Q3 24 | $0.21 | $4.01 | ||
| Q2 24 | $0.26 | $-13.92 | ||
| Q1 24 | $0.31 | $4.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $172.9M | $6.6B |
| 总债务越低越好 | $260.0M | — |
| 股东权益账面价值 | $2.0B | $18.7B |
| 总资产 | $2.5B | $25.6B |
| 负债/权益比越低杠杆越低 | 0.13× | — |
8季度趋势，按日历期对齐
现金及短期投资TECHVRTX
| Q4 25 | $172.9M | $6.6B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | $162.2M | $6.4B | ||
| Q1 25 | $140.7M | $6.2B | ||
| Q4 24 | $177.5M | $6.1B | ||
| Q3 24 | $187.5M | $6.5B | ||
| Q2 24 | $152.9M | $5.8B | ||
| Q1 24 | $145.3M | $10.2B |
总债务TECHVRTX
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
股东权益TECHVRTX
| Q4 25 | $2.0B | $18.7B | ||
| Q3 25 | — | $17.3B | ||
| Q2 25 | $1.9B | $17.2B | ||
| Q1 25 | $2.0B | $16.5B | ||
| Q4 24 | $2.1B | $16.4B | ||
| Q3 24 | $2.1B | $15.6B | ||
| Q2 24 | $2.1B | $14.8B | ||
| Q1 24 | $2.0B | $18.5B |
总资产TECHVRTX
| Q4 25 | $2.5B | $25.6B | ||
| Q3 25 | — | $24.9B | ||
| Q2 25 | $2.6B | $24.0B | ||
| Q1 25 | $2.6B | $22.9B | ||
| Q4 24 | $2.7B | $22.5B | ||
| Q3 24 | $2.7B | $22.2B | ||
| Q2 24 | $2.7B | $20.1B | ||
| Q1 24 | $2.7B | $23.9B |
负债/权益比TECHVRTX
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $498.0M |
| 自由现金流经营现金流 - 资本支出 | — | $348.6M |
| 自由现金流率自由现金流/营收 | — | 10.9% |
| 资本支出强度资本支出/营收 | — | 4.7% |
| 现金转化率经营现金流/净利润 | — | 0.42× |
| 过去12个月自由现金流最近4个季度 | — | $3.2B |
8季度趋势，按日历期对齐
经营现金流TECHVRTX
| Q4 25 | — | $498.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $98.2M | $1.1B | ||
| Q1 25 | $41.1M | $818.9M | ||
| Q4 24 | $84.3M | $584.6M | ||
| Q3 24 | $63.9M | $1.4B | ||
| Q2 24 | $75.5M | $-3.8B | ||
| Q1 24 | $81.0M | $1.3B |
自由现金流TECHVRTX
| Q4 25 | — | $348.6M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $93.3M | $927.4M | ||
| Q1 25 | $31.0M | $778.2M | ||
| Q4 24 | $77.5M | $492.0M | ||
| Q3 24 | $54.7M | $1.3B | ||
| Q2 24 | $57.5M | $-3.8B | ||
| Q1 24 | $64.5M | $1.2B |
自由现金流率TECHVRTX
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | 29.4% | 31.3% | ||
| Q1 25 | 9.8% | 28.1% | ||
| Q4 24 | 26.1% | 16.9% | ||
| Q3 24 | 18.9% | 47.0% | ||
| Q2 24 | 18.8% | -144.5% | ||
| Q1 24 | 21.3% | 46.0% |
资本支出强度TECHVRTX
| Q4 25 | — | 4.7% | ||
| Q3 25 | — | 3.3% | ||
| Q2 25 | 1.5% | 4.9% | ||
| Q1 25 | 3.2% | 1.5% | ||
| Q4 24 | 2.3% | 3.2% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 5.9% | 2.6% | ||
| Q1 24 | 5.4% | 2.5% |
现金转化率TECHVRTX
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.04× | ||
| Q1 25 | 1.82× | 1.27× | ||
| Q4 24 | 2.42× | 0.64× | ||
| Q3 24 | 1.90× | 1.31× | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.65× | 1.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
